Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Novo Nordisk reports strong growth during 2014 to date

Novo Nordisk reports strong growth during 2014 to date

30th October 2014

Novo Nordisk has highlighted the strong progress it has made towards its business goals during the first three quarters of 2014.

In the first nine months of the year, the company generated sales of 64.2 billion Danish kroner (6.79 billion pounds), up by eight percent year on year in local currency terms, with operating profit in local currencies also rising by 11 percent.

Improved sales for products like Levemir and Victoza helped to drive growth, as did the progress made with the continued global rollout of Tresiba.

For 2014, sales growth is now expected to be between seven and nine percent, while the preliminary outlook for 2015 indicates high single-digit growth.

Lars Rebien Sorensen, chief executive officer of Novo Nordisk, said: "In the US, Levemir continues to perform well, and with the approval of Xultophy in Europe we now look forward to launching this product in the first half of 2015."

Earlier this month, the firm was ranked as the world's second-best science employer in the 2014 Science Careers Top Employers Survey, significantly improving on its performance from last year.ADNFCR-8000103-ID-801757411-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.